Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

Author:

Nastoupil Loretta J.1,Kuruvilla John2ORCID,Chavez Julio C.3,Bijou Fontanet4,Witzig Thomas E.5,Santoro Armando6,Flinn Ian W.7,Boccomini Carola8,Kenkre Vaishalee P.9,Corradini Paolo10,Isufi Iris11,Andorsky David J.12,Klein Leonard M.13,Greenwald Daniel R.14,Sangha Randeep15,Shen Frank16,Hagner Patrick16,Li Yan16,Dobmeyer Juergen17,Gong Nian16,Uttamsingh Shailaja16,Pourdehnad Michael16,Ribrag Vincent18ORCID

Affiliation:

1. Department of Lymphoma and Myeloma Division of Cancer Medicine MD Anderson Cancer Center The University of Texas Houston Texas USA

2. Division of Medical Oncology and Hematology Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada

3. H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

4. Institut Bergonié Bordeaux Cedex France

5. Mayo Clinic Rochester Minnesota USA

6. Department of Biomedical Sciences Pieve Emanuele Milan Humanitas University Italy ‐IRCCS Humanitas Research Hospital‐ Humanitas Cancer Center Rozzano Milan Italy

7. Sarah Cannon Research Institute Nashville Tennessee USA

8. SC Ematologia ASOU Città della Salute e della Scienza di Torino Turin Italy

9. Division of Hematology and Oncology University of Wisconsin Madison Wisconsin USA

10. IRCCS Istituto Nazionale dei Tumori University of Milano Milano Italy

11. Yale Cancer Center New Haven Connecticut USA

12. Rocky Mountain Cancer Centers The US Oncology Network Boulder Colorado USA

13. Illinois Cancer Specialists The US Oncology Network Niles Illinois USA

14. Cancer Center of Santa Barbara Santa Barbara California USA

15. Cross Cancer Institute Edmonton Alberta Canada

16. Bristol Myers Squibb Princeton New Jersey USA

17. Centre for Innovation and Translational Research Europe (CITRE) Bristol‐Myers Squibb Company Seville Spain

18. Institut Gustave Roussy Villejuif France

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3